{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:03:32Z","timestamp":1784322212509,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ad.2024.05.011","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T18:35:48Z","timestamp":1717007748000},"page":"T702-T711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["[Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis"],"prefix":"10.1016","volume":"115","author":[{"given":"L.","family":"Puig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Notario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scheneller-Pavelescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Galache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.05.011_bib0275","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ad.2024.05.011_bib0280","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.3390\/ijms21165803","article-title":"Psoriasis and Connective Tissue Diseases","volume":"21","author":"Yamamoto","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ad.2024.05.011_bib0285","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med (Lond)."},{"key":"10.1016\/j.ad.2024.05.011_bib0290","doi-asserted-by":"crossref","first-page":"110464","DOI":"10.1016\/j.intimp.2023.110464","article-title":"Psoriasis and skin cancer - Is there a link?","volume":"121","author":"Balda","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.ad.2024.05.011_bib0295","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.05.011_bib0300","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.05.011_bib0305","first-page":"1109","article-title":"Psoriasis Therapy and Skin Cancer: A Review","volume":"11","author":"Butr\u00f3n-Bris","year":"2021","journal-title":"Life (Basel)."},{"key":"10.1016\/j.ad.2024.05.011_bib0310","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of methotrexate and risk of skin cancer: a nationwide case-control study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br J Cancer."},{"key":"10.1016\/j.ad.2024.05.011_bib0315","doi-asserted-by":"crossref","first-page":"113928","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.ad.2024.05.011_bib0320","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J Exp Med."},{"key":"10.1016\/j.ad.2024.05.011_bib0325","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.ad.2024.05.011_bib0330","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0335","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0340","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Garcia-Doval","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0350","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0355","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.05.011_bib0360","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.05.011_bib0365","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ad.2010.04.002","article-title":"Guidelines on the Use of Methotrexate in Psoriasis","volume":"101","author":"Carretero","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.05.011_bib0370","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ad.2013.01.003","article-title":"Guidelines for the use of acitretin in psoriasis Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Carretero","year":"2013","journal-title":"Actas Dermosifiliogr."},{"issue":"Suppl 3","key":"10.1016\/j.ad.2024.05.011_bib0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jdv.12162","article-title":"Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion","volume":"27","author":"Richard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0380","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0385","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/jca.37015","article-title":"Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer."},{"key":"10.1016\/j.ad.2024.05.011_bib0390","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0395","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0400","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jdv.16683","article-title":"Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0405","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0410","first-page":"68","article-title":"Risk of Skin Cancer with Phototherapy in Moderate-to-Severe Psoriasis: An Updated Systematic Review","volume":"15","author":"Thatiparthi","year":"2022","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0415","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.ad.2024.05.011_bib0420","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0425","first-page":"979","article-title":"The use of cyclosporine in dermatology","volume":"11","author":"Dehesa","year":"2012","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0430","doi-asserted-by":"crossref","first-page":"696597","DOI":"10.3389\/fmed.2021.696597","article-title":"Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease","volume":"8","author":"Arora","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.ad.2024.05.011_bib0435","unstructured":"Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) [actualizado 23 Ene 2023; accessed 28 Jul 2023]. Available from https:\/\/www.medicines.org.uk\/emc\/product\/1034\/smpc#gref"},{"key":"10.1016\/j.ad.2024.05.011_bib0440","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.4081\/dr.2022.9091","article-title":"Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients","volume":"14","author":"Burlando","year":"2022","journal-title":"Dermatol Reports."},{"key":"10.1016\/j.ad.2024.05.011_bib0445","doi-asserted-by":"crossref","first-page":"e15066","DOI":"10.1111\/dth.15066","article-title":"Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study","volume":"34","author":"Corazza","year":"2021","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2024.05.011_bib0450","doi-asserted-by":"crossref","first-page":"adv4526","DOI":"10.2340\/actadv.v103.4526","article-title":"Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study","volume":"103","author":"Gnesotto","year":"2023","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2024.05.011_bib0455","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/jid.2010.416","article-title":"Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?","volume":"131","author":"Garc\u00eda-Caballero","year":"2011","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0460","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/jid.2011.105","article-title":"Mechanisms of drug action: the potential of dimethylfumarate for the treatment of neoplasms","volume":"131","author":"Chen","year":"2011","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0465","first-page":"23","article-title":"Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature","volume":"15","author":"Gambardella","year":"2022","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0470","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ajd.12889","article-title":"Psoriasis and cancer An Australian\/New Zealand narrative","volume":"60","author":"Rademaker","year":"2019","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0475","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse Effects of Low-Dose Methotrexate: A Randomized Trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.ad.2024.05.011_bib0480","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0485","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ad.2024.05.011_bib0490","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Gu\u00eda de Pr\u00e1tica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide; 2019 [accessed 28 Jul 2023]. Available from: https:\/\/www.ser.es\/wp-content\/uploads\/2019\/03\/Guia-de-Practica-Clinica-para-el-Manejo-de-Pacientes-con-Artritis-Reumatoide.pdf"},{"key":"10.1016\/j.ad.2024.05.011_bib0495","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ad.2024.05.011_bib0500","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"key":"10.1016\/j.ad.2024.05.011_bib0505","doi-asserted-by":"crossref","first-page":"108189","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.ad.2024.05.011_bib0510","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0515","doi-asserted-by":"crossref","first-page":"e14830","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2024.05.011_bib0520","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.05.011_bib0525","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.ad.2024.05.011_bib0530","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.ad.2024.05.011_bib0535","article-title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep."},{"key":"10.1016\/j.ad.2024.05.011_bib0540","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol Ther (Heidelb)."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024004320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024004320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:41:20Z","timestamp":1719794480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024004320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0001731024004320"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.05.011","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}